Genitourinary medical oncologist @UTMDAnderson. Likes: clinical trials, cycling, Miami hurricanes, Jeopardy!
Houston, TX
Joined July 2018
- Tweets386
- Following510
- Followers464
- Likes1.8K
Mike Glover retweeted
Voting for the ASCO Election is now open. I am honored to be running as one of the candidates for the ASCO Board. Visit asco.org/election to learn more about the candidates and place your vote!
Mike Glover retweeted
🚨📝checkout our newest #bladdercancer paper. Skin tox (🟡 on swimmers plot) common and early in EVP and linked to better outcomes in la/mUC. We also provide landmark and Simon-Makuch analyses.
🙏 stat editors @JAMANetworkOpen
🌟🥇@DrZachariahT
Co-mentor @DocMattCampbell – at Madrid, Spain
In advanced #UrothelialCarcinoma, treatment-emergent skin toxic effects during first-line enfortumab vedotin plus pembrolizumab were associated with longer overall survival. ja.ma/4k88Qvf
ALT A horizontal bar chart showing time since EVP indication in months on the x-axis, accompanied by categorical side columns for skin toxic effects, best response, and vital status. Below is a density plot peaking sharply near zero.
Mike Glover retweeted
Thrilled to share updated results from JNJ-6143, the AR-BRD4 RIPTAC therapy, presented by @BGarmezy. Totally novel MOA was well tolerated, oral pill and produced significant benefit for pts (PSA90 50%, ORR 68%). P2 trial active now and more coming. Lots of potential!
Mike Glover retweeted
(1/4) Here's our clinical lab’s latest work led by @MitchellBoshkos, PGY-3, evaluating how cardiometabolic factors influence response to pre-operative ADT +/- ARPI in localized HRPCa in @pcan_journal
tinyurl.com/3u8r4vf9
Mike Glover retweeted
The pre-operative model to learn how immunotherapies can improve outcomes in prostate cancer. Outstanding talk by @sumit_subudhi @UTMDAnderson
Mike Glover retweeted
I wonder how you would treat a patient after nephro-uretectomy for a high grade, T3N0M0 upper tract urothelial cancer. The tumor is PD-L1+ve and ctDNA-ve. The pateint is not eligible for cisplatin. @DrChoueiri @montypal @PGrivasMDPhD @OncoAlert @Annals_Oncology
22%Surveillance
22%Gem/carbo
31%Nivolumab
24%EV Pembro
565 votes • Final results Mike Glover retweeted
Your patient has had nephrectomy for high-risk clear cell RCC. The next decision: Surveillance, Pembrolizumab, or Pembrolizumab + belzutifan. Is adjuvant justified when surgery may already have been curative? Our new commentary explores this dilemma. 🧵bit.ly/4jkism6
Mike Glover retweeted
Much appreciated🙏Indeed a broader lesson about rare cancers is that the tools needed to find this dependency (IHC, EGFR mAbs etc.) have existed for decades. What was missing was aggregated samples, purpose-built models, and a mechanism to clinically act on the finding quickly.
Mike Glover retweeted
Happy to share a recently published investigation from @UTMDAnderson on the spectrum of somatic-type malignancies, origin sites and emergence patterns.
Huge thanks to @DocMattCampbell @OAlhalabiMD @andrewjohnsmd @glovedoc for unparalleled mentorship.
academic.oup.com/oncolo/arti…
Mike Glover retweeted
🚀 Now enrolling @UTMDAnderson: STaRMC trial testing sacituzumab tirumotecan in SMARCB1-deficient #RenanMedullaryCarcinoma
👉 clinicaltrials.gov/study/NCT… RMC outcomes have improved but we still lose too many. A key step to #EndRMC. #MsaouelLab #RareCancers #kidneycancer @KidneyCancer
Mike Glover retweeted
Panitumumab improves survival for patients with RMC, a rare and aggressive variant renal cancer. @PavlosMsaouel is advancing tx for RMC, inspiring! #ASCO26
Mike Glover retweeted
@emanuele_crupi presenting #ASCO26 the phase 2 study results of the GemFLP regimen in urinary tract adenocarcinoma. @ASCO @DocMattCampbell @PGrivasMDPhD @neerajaiims @glovedoc @SGoswamiMDPhD @mjmoussa_ @OncHahn @OAlhalabiMD
Mike Glover retweeted
If your employer-sponsored insurance copay for a generic is over $15, then 80% of the time, you are overpaying.
In @AnnalsofIM, we analyzed nationwide data on employer plans vs @mcuban’s @costplusdrugs.
Here is a breakdown on who stands to save most. 🧵
NEW: Many patients could pay less for generic drugs by purchasing directly from the Mark Cuban Cost Plus Drug Company @costplusdrugs instead of using employer-sponsored insurance. The findings suggest that patients should consider direct-to-consumer pharmacies for higher out-of-pocket cost #prescriptions. bit.ly/4uZ93Da
Mike Glover retweeted
Honored to present results from the phase II GemFLP trial conducted at The University of Texas MD Anderson Cancer Center in advanced urachal and non-urachal urinary tract adenocarcinoma.
Rapid Oral Session — Hall D2
Monday, June 1 | 8:00 AM #ASCO26
@mjmoussa_ @DocMattCampbell
Mike Glover retweeted
Ab#4520 @ASCO #ASCO26 by @PavlosMsaouel👉 bit.ly/4nHgVqx👉Remarkable clinical activity of EGFR blockade (panitumumab) in SMARCB1-deficient renal medullary mRCC #kidneycancer👉Median PFS 5.8 mo & median OS 9.5 mo👇@NikiZacharias @BradMcG04 @OncoAlert @urotoday @kidneycan
Mike Glover retweeted
📺 Watch @DocMattCampbell and @mjmoussa_ of @UTMDAnderson share findings from their study exploring the use of immune checkpoint inhibitors in patients with deficient mismatch repair/microsatellite instability–high #UTUC: buff.ly/YXgJYJW
Mike Glover retweeted
Dr. Larry Einhorn is known for revolutionizing testicular cancer treatment. His research resulted in a groundbreaking treatment that moved the survival rate from 5% to 95%. This testicular cancer awareness month, and every month, we are grateful to have him as a member of our Board of Directors and pillar of the Conquer Cancer community.
#testiculatcancerawareness #testicularcancerawarenessmonth #ResearchConquersCancer #ConquerCancer
Mike Glover retweeted
Really grateful for the opportunity to summarise key findings from our presentation at ASCO GU’26 on the @VuMedi platform. Check out their website for the latest updates in biomedicine. @DocMattCampbell @OAlhalabiMD @CYJiangMD @glovedoc @andrewjohnsmd
vumedi.com/video/asco-gu-202…
Mike Glover retweeted
Stomp Out Cancer in honor of Dan Hund and his battle against adrenal cancer is in its 6th year stompoutcancer4dan.com/ all funds support rare tumor research with a new trial. Fill out a bracket at ESPN group is Dan Hund Memorial password stompoutcancer.
Mike Glover retweeted
PhaseII trial of cabozantinib in refractory germ-cell tumors. Nice to see activity and clinical benefit in very refractory/heavily pretreated population. Important to continue drug development in this disease! @JenniferKingMD @IUCancerCenter @TestesCancer @TestesCancer
